BR0309278A - Composto, composição, métodos para modular a atividade da cinesina ksp, para inibir a ksp, para o tratamento de uma doença proliferativa celular, e, uso de um composto - Google Patents

Composto, composição, métodos para modular a atividade da cinesina ksp, para inibir a ksp, para o tratamento de uma doença proliferativa celular, e, uso de um composto

Info

Publication number
BR0309278A
BR0309278A BR0309278-0A BR0309278A BR0309278A BR 0309278 A BR0309278 A BR 0309278A BR 0309278 A BR0309278 A BR 0309278A BR 0309278 A BR0309278 A BR 0309278A
Authority
BR
Brazil
Prior art keywords
compound
ksp
modulating
composition
methods
Prior art date
Application number
BR0309278-0A
Other languages
English (en)
Inventor
Andrew Macdonald
Gustave Bergnes
Bainian Feng
David J C Morgans
Steven David Knight
Kenneth A Newlander
Dashyant Dhanak
Christopher S Brook
Original Assignee
Cytokinetics Inc
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytokinetics Inc, Smithkline Beecham Corp filed Critical Cytokinetics Inc
Publication of BR0309278A publication Critical patent/BR0309278A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/34—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only
    • C07D311/36—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only not hydrogenated in the hetero ring, e.g. isoflavones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

"COMPOSTO, COMPOSIçãO, MéTODOS PARA MODULAR A ATIVIDADE DA CINESINA KSP, PARA INIBIR A KSP, PARA O TRATAMENTO DE UMA DOENçA PROLIFERATIVA CELULAR, E, USO DE UM COMPOSTO". São descritos compostos úteis para tratar doenças e distúrbios proliferativos celulares, modulando-se a atividade de KSP.
BR0309278-0A 2002-04-17 2003-04-11 Composto, composição, métodos para modular a atividade da cinesina ksp, para inibir a ksp, para o tratamento de uma doença proliferativa celular, e, uso de um composto BR0309278A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37345402P 2002-04-17 2002-04-17
US41068202P 2002-09-13 2002-09-13
PCT/US2003/011432 WO2003088903A2 (en) 2002-04-17 2003-04-11 Compounds, compositions, and methods

Publications (1)

Publication Number Publication Date
BR0309278A true BR0309278A (pt) 2005-04-26

Family

ID=29254526

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0309278-0A BR0309278A (pt) 2002-04-17 2003-04-11 Composto, composição, métodos para modular a atividade da cinesina ksp, para inibir a ksp, para o tratamento de uma doença proliferativa celular, e, uso de um composto

Country Status (22)

Country Link
US (7) US6924376B2 (pt)
EP (1) EP1511734B1 (pt)
JP (1) JP4664597B2 (pt)
KR (1) KR101052816B1 (pt)
CN (1) CN100381437C (pt)
AR (1) AR039419A1 (pt)
AT (1) ATE471931T1 (pt)
AU (1) AU2003234733B2 (pt)
BR (1) BR0309278A (pt)
CA (1) CA2482041C (pt)
DE (1) DE60333094D1 (pt)
DK (1) DK1511734T3 (pt)
HK (1) HK1070656A1 (pt)
IL (2) IL164581A (pt)
MX (1) MXPA04010240A (pt)
MY (1) MY140169A (pt)
NO (1) NO330433B1 (pt)
NZ (1) NZ536190A (pt)
PL (1) PL211300B1 (pt)
RU (1) RU2308454C9 (pt)
TW (1) TWI282337B (pt)
WO (1) WO2003088903A2 (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL211300B1 (pl) 2002-04-17 2012-05-31 Cytokinetics Inc Związek i kompozycja zawierająca ten związek
DE60326248D1 (de) 2002-07-17 2009-04-02 Cytokinetics Inc Verbindungen, zusammensetzungen und verfahren zur behandlung von zellulären proliferativen erkrankungen
WO2004024086A2 (en) * 2002-09-13 2004-03-25 Cytokinetics, Inc. Compounds, compositions and methods
WO2004078758A1 (en) * 2003-03-07 2004-09-16 Astrazeneca Ab Novel fused heterocycles and uses thereof
WO2006018628A1 (en) * 2003-03-07 2006-02-23 Astrazeneca Ab Enantiomers of selected fused pyrimidones and uses in the treatment and preventi on of cancer
EP1670456A2 (en) * 2003-10-06 2006-06-21 Cytokinetics, Inc. Compounds, compositions and methods
JP2007527917A (ja) * 2004-03-08 2007-10-04 ワイス イオンチャンネルモジュレーター
WO2005087747A1 (en) * 2004-03-08 2005-09-22 Wyeth Ion channel modulators
RU2385867C2 (ru) 2004-05-21 2010-04-10 Новартис Аг Замещенные производные хинолина как ингибиторы митотического кинезина
CA2574204A1 (en) * 2004-07-22 2006-01-26 Astrazeneca Ab Fused pyrimidones useful in the treatment and the prevention of cancer
UY29070A1 (es) * 2004-08-18 2006-03-31 Astrazeneca Ab Enantiómeros de heterocíclicos fusionados y sus usos
US20060041128A1 (en) * 2004-08-18 2006-02-23 Astrazeneca Ab Selected fused heterocyclics and uses thereof
CN101023086A (zh) * 2004-08-18 2007-08-22 阿斯利康(瑞典)有限公司 选择性稠合的杂环及其应用
US20100093767A1 (en) * 2004-12-03 2010-04-15 Takeda San Diego, Inc. Mitotic Kinase Inhibitors
EP1956908A2 (en) * 2005-12-08 2008-08-20 Cytokinetics, Inc. Certain compositions and methods of treatment
WO2007106818A1 (en) * 2006-03-13 2007-09-20 University Of Florida Research Foundation, Inc. Synthesis of pentafluorosulfanyl (sf5)-substituted heterocycles and alkynes
WO2007134183A2 (en) * 2006-05-13 2007-11-22 Advanced Technology Materials, Inc. Chemical reagent delivery system utilizing ionic liquid storage medium
CN101622247A (zh) 2007-01-05 2010-01-06 诺瓦提斯公司 作为驱动蛋白纺锤体蛋白抑制剂的咪唑衍生物
KR102263079B1 (ko) * 2009-11-05 2021-06-10 리젠 파마슈티컬스 소시에떼 아노님 신규한 벤조피란 키나제 조절제
MX352661B (es) * 2009-11-05 2017-12-04 Rhizen Pharmaceuticals S A Star Moduladores novedosos de benzopiran cinasa.
WO2012066330A1 (en) 2010-11-17 2012-05-24 Heptares Therapeutics Limited Compounds useful as a2a receptor inhibitors
CA2833935C (en) * 2011-05-04 2020-09-15 Dhanapalan Nagarathnam Novel compounds as modulators of protein kinases
EP2870157B1 (en) 2012-07-04 2017-08-30 Rhizen Pharmaceuticals S.A. Selective pi3k delta inhibitors
EP2931707A4 (en) * 2012-12-13 2016-07-20 Glaxosmithkline Llc AMPLIFIER OF ZEST HOMOLOG 2 INHIBITORS
US9556157B2 (en) 2013-07-10 2017-01-31 Glaxosmithkline Intellectual Property (No.2) Limited Enhancer of zeste homolog 2 inhibitors
JP2018521044A (ja) * 2015-07-23 2018-08-02 ファーマケア，インク． リシルオキシダーゼ様２阻害剤とその使用
ES2880766T3 (es) 2016-02-09 2021-11-25 Pharmakea Inc Inhibidores de quinolinona lisil oxidasa similar al tipo 2 y usos de los mismos
CN111991389B (zh) * 2020-09-17 2021-11-23 陕西科技大学 Sb-743921用于制备抗真菌药物的用途

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US169159A (en) * 1875-10-26 Improvement in corsets
US116400A (en) * 1871-06-27 Improvement in heels for boots and shoes
US55054A (en) * 1866-05-29 Improvement in lamp-chimneys
GB728767A (en) * 1951-10-12 1955-04-27 Wander Ag Dr A 2-substituted chromone compounds, and a method of making same
NL84159C (pt) 1952-06-30
DE3063585D1 (en) * 1979-05-19 1983-07-07 Beecham Group Plc Chroman derivatives, processes for their preparation and pharmaceutical compositions containing them
DE3177130D1 (de) * 1980-08-30 1990-01-11 Hoechst Ag Aminosaeurederivate, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung.
US4434296A (en) * 1982-05-17 1984-02-28 The Upjohn Company Process for preparing intermediates for antiatherosclerotic compounds
US4459420A (en) 1982-05-17 1984-07-10 The Upjohn Company Pyrogallol synthesis of anti-atherogenic furochromones
US4434295A (en) 1982-05-17 1984-02-28 The Upjohn Company Anti-atherosclerotic 6,7-dihydro-7,7-disubstituted-khellin analogs
US4482558A (en) * 1982-06-18 1984-11-13 Pfizer Inc. Antifungal amide and urea derivatives of (3-amino-2-aryl-2-hydroxyprop-1-yl)-1H-1,2,4-triazoles
JPS62201882A (ja) * 1985-11-18 1987-09-05 Yamanouchi Pharmaceut Co Ltd イソフラボン誘導体
IN164232B (pt) * 1986-04-11 1989-02-04 Hoechst India
IL85554A0 (en) * 1987-03-02 1988-08-31 Takeda Chemical Industries Ltd Chromone derivatives
JPH0753725B2 (ja) * 1987-10-08 1995-06-07 富山化学工業株式会社 ４ｈ―１―ベンゾピラン―４―オン誘導体およびその塩、それらの製造法並びにそれらを含有する抗炎症剤
USH1427H (en) 1988-04-06 1995-04-04 Briet; Phillipe Substituted flavonoid compounds, their salts, their manufacture and their use in combination with interleukin-2
MA21528A1 (fr) 1988-04-06 1989-12-31 Lipha Composants substituants du flavonoide, leurs sels, leurs manufactures et produits contenant ces matieres .
US5180717A (en) * 1988-08-16 1993-01-19 The Upjohn Company Bivalent ligands effective for blocking ACAT enzyme for lowering plasma triglycerides and for elevating HDL cholesterol
US5304548A (en) * 1988-08-16 1994-04-19 The Upjohn Company Bivalent ligands effective for blocking ACAT enzyme for lowering plasma triglycerides and for elevating HDL cholesterol
DE3836676A1 (de) 1988-10-28 1990-05-03 Hoechst Ag Die verwendung von 4h-1-benzopyran-4-on-derivaten, neue 4h-1-benzopyran-4-on-derivate und diese enthaltende arzneimittel
US5284856A (en) * 1988-10-28 1994-02-08 Hoechst Aktiengesellschaft Oncogene-encoded kinases inhibition using 4-H-1-benzopyran-4-one derivatives
US5703075A (en) * 1988-12-21 1997-12-30 Pharmacia & Upjohn Company Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones
JPH04502322A (ja) * 1988-12-21 1992-04-23 ジ・アップジョン・カンパニー 抗アテローム性動脈硬化症性および抗血栓性１―ベンゾピラン―４―オン類および２―アミノ―１，３―ベンゾオキサジン―４―オン類
US4977162A (en) * 1989-07-13 1990-12-11 Rorer Pharmaceutical Corporation Quinolinyl-chromone derivatives and use for treatment of hypersensitive ailments
US5082849A (en) * 1989-07-13 1992-01-21 Huang Fu Chich Quinolinyl-benzopyran derivatives as antagonists of leukotriene D4
US5032598A (en) * 1989-12-08 1991-07-16 Merck & Co., Inc. Nitrogens containing heterocyclic compounds as class III antiarrhythmic agents
US5215989A (en) * 1989-12-08 1993-06-01 Merck & Co., Inc. Nitrogen-containing heterocyclic compounds as class III antiarrhythmic agents
CA2081577A1 (en) 1990-06-20 1991-12-21 Ronald B. Gammill Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1, 3-benzoxazine-4-ones
AU650036B2 (en) * 1990-07-25 1994-06-09 Teijin Limited Benzopyran derivative, production thereof, and pharmaceutical composition containing the same
EP0503091A4 (en) 1990-09-28 1993-03-10 Ube Industries, Ltd. Process for producing diester of carbonic acid
WO1992006086A1 (en) 1990-10-01 1992-04-16 Janssen Pharmaceutica N.V. Novel 4-piperidinylcarbonyl derivatives
JPH05301813A (ja) 1991-10-15 1993-11-16 Kao Corp 皮膚外用剤
HUT68636A (en) 1992-01-24 1995-07-28 Teijin Ltd Benzopyrane derivatives, process for producing them, and pharmaceutical compositions containing them
US5605896A (en) * 1992-02-25 1997-02-25 Recordati S.A., Chemical And Pharmaceutical Company Bicyclic heterocyclic derivatives having α1 adrenergic and 5HT1A activities
FR2693196B1 (fr) 1992-07-03 1994-12-23 Lipha Dérivés de benzopyranone ou de benzothiopyranone, procédé de préparation et composition pharmaceutique les contenant.
JP2579303Y2 (ja) * 1992-08-14 1998-08-27 株式会社共立 バリカン形刈払機
MX9603570A (es) * 1994-02-23 1997-03-29 Chiron Corp Metodo y composiciones para incrementar la vida media en suero de agentes farmacologicamente activos.
EP0764159B1 (en) 1994-06-10 2000-08-09 Smithkline Beecham Plc C -4 amide substituted compounds and their use as therapeutic agents
US5607928A (en) * 1994-08-05 1997-03-04 Zeneca Limited Carbapenem derivatives containing a bicyclic ketone substituent and their use as anti-infectives
GB9417969D0 (en) 1994-09-07 1994-10-26 King S College London Alkaloids and derivatives thereof
US5602171A (en) * 1995-06-07 1997-02-11 Sugen Inc. Methods of inhibiting phosphatase activity and treatment of disorders associated therewith using naphthopyrones and derivatives thereof
WO1997014419A1 (en) 1995-10-20 1997-04-24 Flora Inc. Transdermal delivery of alpha adrenoceptor blocking agents
NL1003520C2 (nl) 1996-07-05 1998-01-07 Stork Amsterdam Sterilisatie-inrichting en werkwijze voor het steriliseren van voorwerpen.
US5908934A (en) 1996-09-26 1999-06-01 Bristol-Myers Squibb Company Process for the preparation of chiral ketone intermediates useful for the preparation of flavopiridol and analogs
GB9807779D0 (en) 1998-04-09 1998-06-10 Ciba Geigy Ag Organic compounds
US6028088A (en) 1998-10-30 2000-02-22 The University Of Mississippi Flavonoid derivatives
US6087385A (en) * 1998-10-30 2000-07-11 University Of Mississippi Flavonoid derivatives
DE19850131A1 (de) 1998-10-30 2000-05-04 Merck Patent Gmbh Chromenon- und Chromanonderivate
DE19858341A1 (de) * 1998-12-17 2000-06-21 Merck Patent Gmbh Chromanderivate
US6399633B1 (en) * 1999-02-01 2002-06-04 Aventis Pharmaceuticals Inc. Use of 4-H-1-benzopryan-4-one derivatives as inhibitors of smooth muscle cell proliferation
GB9911071D0 (en) 1999-05-12 1999-07-14 Darwin Discovery Ltd Hydroxamic and carboxylic acid derivatives
DE60031285T2 (de) * 1999-08-27 2007-08-30 Chemocentryx Inc., Mountain View Heterozyclische verbindungen und verfahren zur modulierung von cxcr3 funktion
GB9920910D0 (en) 1999-09-03 1999-11-10 Indena Spa Novel chalcones
GB9920912D0 (en) * 1999-09-03 1999-11-10 Indena Spa Novel derivatives of flavones,xanthones and coumarins
EP1216234B1 (en) * 1999-09-16 2004-12-29 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
US6552016B1 (en) 1999-10-14 2003-04-22 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
US6545004B1 (en) * 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US6683192B2 (en) 2000-03-30 2004-01-27 Curis, Inc. Small organic molecule regulators of cell proliferation
CN1433410A (zh) * 2000-05-03 2003-07-30 株式会社Lg生命科学 具有3－羟基色烯－4－酮结构的cdk抑制剂
US6559145B2 (en) 2000-07-12 2003-05-06 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
DE10036003A1 (de) 2000-07-25 2002-02-14 Aventis Cropscience Gmbh Herbizide Mittel
US6903121B1 (en) 2000-08-17 2005-06-07 Allergan, Inc. Treatment of tumors with acetylenes disubstituted with a phenyl or heteroaromatic group and a substituted chromanyl, thiochromanyl or tetrahydroquinolinyl group in combination with other anti-tumor agents
EP1343505A1 (en) 2000-12-11 2003-09-17 Tularik Inc. Cxcr3 antagonists
JP2002322169A (ja) 2001-02-21 2002-11-08 Sankyo Co Ltd クロメン誘導体
BR0211513A (pt) 2001-07-27 2005-08-30 Curis Inc Mediadores de caminhos sinalizantes de hedgehog, composições e usos relacionados ao mesmo
SE0103648D0 (sv) * 2001-11-01 2001-11-01 Astrazeneca Ab Therapeutic quinolone compounds
JP2005511581A (ja) 2001-11-07 2005-04-28 メルク　エンド　カムパニー　インコーポレーテッド 有糸分裂キネシン阻害剤
DE60231439D1 (de) 2001-12-06 2009-04-16 Merck & Co Inc Mitotische kinesinhemmer
AU2002351183B2 (en) 2001-12-06 2008-05-08 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
DE60232994D1 (de) 2001-12-06 2009-08-27 Merck & Co Inc Inhibitoren von mitotischem kinesin
CA2467722A1 (en) 2001-12-06 2003-06-19 Merck & Co., Inc. Thienopyrimidinone derivatives as mitotic kinesin inhibitors
EP1465896A4 (en) 2001-12-06 2006-01-11 Merck & Co Inc MITOTIC INHIBITORS OF KINESIN
AU2003249597B2 (en) 2002-03-08 2007-06-28 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
PL211300B1 (pl) * 2002-04-17 2012-05-31 Cytokinetics Inc Związek i kompozycja zawierająca ten związek
AU2003231799A1 (en) 2002-05-23 2003-12-12 Merck & Co., Inc. Mitotic kinesin inhibitors
DE60312516T2 (de) 2002-06-14 2007-11-22 Merck & Co., Inc. Inhibitoren von mitotischem kinesin
BR0311784A (pt) 2002-06-14 2005-03-08 Merck & Co Inc Composto, composição farmacêutica, métodos de tratar ou prevenir o câncer, de modular a formação do fuso mitótico e de inibir a cinesina mitótica e processo para fabricar uma composição farmacêutica
EP1551962A4 (en) 2002-07-08 2007-08-01 Merck & Co Inc MITOTIC KINESIN BINDING CENTER
DE60326248D1 (de) 2002-07-17 2009-04-02 Cytokinetics Inc Verbindungen, zusammensetzungen und verfahren zur behandlung von zellulären proliferativen erkrankungen
WO2004014388A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc 6,6-fused heteroaryl derivatives as matrix metalloproteinase inhibitors
WO2004024086A2 (en) * 2002-09-13 2004-03-25 Cytokinetics, Inc. Compounds, compositions and methods
EP1670456A2 (en) 2003-10-06 2006-06-21 Cytokinetics, Inc. Compounds, compositions and methods
WO2005040163A1 (en) 2003-10-28 2005-05-06 Dr. Reddy's Laboratories Ltd Heterocyclic compounds that block the effects of advanced glycation end products (age)
JP4502322B2 (ja) 2004-11-08 2010-07-14 Ａｇｃテクノグラス株式会社 ガラス管の曲げ加工方法およびその成形用金型

Also Published As

Publication number Publication date
RU2004133325A (ru) 2005-10-27
US20130053436A1 (en) 2013-02-28
NO20044662L (no) 2005-01-14
KR101052816B1 (ko) 2011-07-29
US20040082638A1 (en) 2004-04-29
US7491746B2 (en) 2009-02-17
CN1662508A (zh) 2005-08-31
IL164581A0 (en) 2005-12-18
DK1511734T3 (da) 2010-08-02
US6924376B2 (en) 2005-08-02
US20110230550A1 (en) 2011-09-22
CA2482041C (en) 2012-06-05
TWI282337B (en) 2007-06-11
RU2308454C2 (ru) 2007-10-20
DE60333094D1 (de) 2010-08-05
JP4664597B2 (ja) 2011-04-06
US8119678B2 (en) 2012-02-21
CN100381437C (zh) 2008-04-16
US20090005580A1 (en) 2009-01-01
EP1511734A2 (en) 2005-03-09
AU2003234733B2 (en) 2009-01-29
PL373577A1 (en) 2005-09-05
NZ536190A (en) 2007-08-31
TW200408634A (en) 2004-06-01
US7629477B2 (en) 2009-12-08
WO2003088903A3 (en) 2004-09-30
PL211300B1 (pl) 2012-05-31
US8633236B2 (en) 2014-01-21
US8329928B2 (en) 2012-12-11
US20060020008A1 (en) 2006-01-26
WO2003088903A2 (en) 2003-10-30
US20100105767A1 (en) 2010-04-29
RU2308454C9 (ru) 2008-05-10
AU2003234733A1 (en) 2003-11-03
KR20050036908A (ko) 2005-04-20
JP2005523312A (ja) 2005-08-04
HK1070656A1 (en) 2005-06-24
IL164581A (en) 2009-11-18
MXPA04010240A (es) 2005-06-08
EP1511734B1 (en) 2010-06-23
US20120209012A1 (en) 2012-08-16
US7919524B2 (en) 2011-04-05
CA2482041A1 (en) 2003-10-30
NO330433B1 (no) 2011-04-11
MY140169A (en) 2009-11-30
AR039419A1 (es) 2005-02-16
ATE471931T1 (de) 2010-07-15
IL188954A (en) 2011-02-28
EP1511734A4 (en) 2006-05-10

Similar Documents

Publication Publication Date Title
BR0309278A (pt) Composto, composição, métodos para modular a atividade da cinesina ksp, para inibir a ksp, para o tratamento de uma doença proliferativa celular, e, uso de um composto
MY140767A (en) Compounds, methods and compositions
WO2003103575A3 (en) COMPOUNDS, COMPOSITIONS AND METHODS
BR0111898A (pt) Métodos de tratamento de doenças de proliferação celular, e de um distúrbio associado com a atividade de cinesina ksp, método de inibição da cinesina ksp, composto, método de triagem de moduladores da cinesina kps, e, método de triagem de compostos que se ligam à cinesina ksp
BR0015110A (pt) Métodos de tratamento de doenças de proliferação celular, de tratamento de um distúrbio associado com a atividade da cinesina ksp, de inibição da cinesina ksp, de triagem de moduladores da cinesina kps e de triagem de compostos que se ligam na cinesina ksp, e, compostos
BRPI0510663A (pt) pelo menos uma entidade quìmica, composição, métodos para modular atividade da cinesina cenp-e, para inibir cenp-e, e para tratar uma doença proliferativa celular, e, uso de pelo menos uma entidade quìmica
WO2004018058A3 (en) Compounds, compositions, and methods
BRPI0307351B8 (pt) composto, composição farmacêutica, uso de um composto, e, processo para preparar um composto
SE9900100D0 (sv) New compounds
SE9903760D0 (sv) New compounds
BRPI0411743A (pt) método e composições para tratar doenças relacionadas a amilóides
NO20052267L (no) Forbindelser, Preparater og Metoder
WO2004009036A3 (en) Compounds compositions and methods
DE60045508D1 (de) Dalda-analoge und ihre verwendung
BR0309343A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
AU5338401A (en) Methods and compositions for modulating alpha adrenergic receptor activity
BR0316458A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto
SE9802208D0 (sv) Novel compounds
AU2003252025A8 (en) Compounds, compositions, and methods
BR0307903A (pt) derivados de arilsulfona
WO2004034972A3 (en) Compounds, compositions, and methods
BR0011339A (pt) Composto, uso, e processo para preparar o mesmo, composição farmacêutica, e, método para tratar uma condição de doença mediada por metaloproteinase
WO2005046588A3 (en) Compounds, compositions, and methods
WO2004064741A3 (en) Compounds, compositions, and methods
BR0309996A (pt) Composto, composição farmacêutica, método de tratar ou melhorar doenças ou condições proliferativas, uso de um composto, e, método de tratar ou melhorar doenças inflamatórias

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA INT.CL: C07D 233/02, C07D 311/04, A61K 31/352, A61K 31/464, A61P 35/00

Ipc: C07D 233/02 (2011.01), C07D 311/04 (2011.01), A61K

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL